D
David Spiegel
Researcher at Stanford University
Publications - 838
Citations - 50967
David Spiegel is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 106, co-authored 733 publications receiving 46276 citations. Previous affiliations of David Spiegel include Tel Aviv University & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Implementation of a virtual, on-demand, molecular tumor board at a large, multi-clinic, community oncology practice.
Andrew J. McKenzie,Carissa Maree. Jones,Emma G. Sturgill,Mary Lynne Capps,Larry Edward Bilbrey,David Spiegel,Meredith Ann McKean,Stephen M. Schleicher +7 more
TL;DR: An on-demand virtual MTB (vMTB) is feasible within an engaged community oncology practice with investments in bioinformatics, decision support software tools, and a team of precision oncologists experts supported by a robust clinical trial menu.
Patent
Advanced glycation end-product breaking biocatalysts
TL;DR: In this article, a method for removing glucosepane from one or more proteins in a subject is described. But this method requires the subject to be given an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-13 or a biologically active fragment thereof.
Journal ArticleDOI
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
Richard Huang,David P. Carbone,Gerald Li,Alexa B. Schrock,Ryon P. Graf,Liangliang Zhang,Karthikeyan Murugesan,Jeffrey S. Ross,Khaled A. Tolba,Jacob Sands,Geoffrey R. Oxnard,David Spiegel +11 more
TL;DR: In this article , the complementary roles of tumor mutational burden (TMB) and programmed death ligand-1 (PD-L1) immunohistochemistry (IHC) to inform first-line therapy using a large real-world (rw) data set were examined.
Journal ArticleDOI
8P Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer
Stephanie Lheureux,Emily Brown Rosen,David Spiegel,Martin Højgaard,E. Fontana,Niharika B. Mettu,L. Carter,S. Patel,Robert Papp,Suzanne May,P Mohamadi Nejad,Danielle B. Ulanet,Marisa J. Wainszelbaum,Petra Manley,Maria Koehler,Adrian J. Fretland,Ruth Plummer,Timothy A. Yap +17 more
TL;DR: RP-3500 is an oral ATR inhibitor (ATRi) in development for the treatment of patients (pts) with advanced solid tumors carrying alterations in ATRi-sensitizing genes as discussed by the authors .